Despite innumerable studies on lung cancer, many aspects of the disease have yet to be understood, including the role played by the retinoblastoma-related protein Rb2/p130 in the evolution of the disease.
In a new study, researchers from the Sba…
Tumor cells have evolved a crafty scheme for protecting themselves from the killing power of the host immune system; in part, they disable the immune response. New studies implicate a receptor for prostaglandin E2 (PGE2) in this phenomenon of tumor-induced immune suppression. The findings, published in the March 1 Journal of Clinical Investigation, suggest that drugs that block the PGE2 receptor, called EP2, might restore the immune system’s tumor-killing capacity.